- Home
- PGY vs GYRE Comparison
PGY vs GYRE Comparison
Compare PGY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- GYRE
- Stock Information
- Founded
- PGY 2016
- GYRE 2002
- Country
- PGY United States
- GYRE United States
- Employees
- PGY N/A
- GYRE N/A
- Industry
- PGY Finance: Consumer Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- GYRE Health Care
- Exchange
- PGY Nasdaq
- GYRE Nasdaq
- Market Cap
- PGY 1.1B
- GYRE 997.3M
- IPO Year
- PGY N/A
- GYRE N/A
- Fundamental
- Price
- PGY $14.50
- GYRE $11.54
- Analyst Decision
- PGY Strong Buy
- GYRE
- Analyst Count
- PGY 8
- GYRE 0
- Target Price
- PGY $21.19
- GYRE N/A
- AVG Volume (30 Days)
- PGY 4.1M
- GYRE 53.5K
- Earning Date
- PGY 02-13-2025
- GYRE 03-25-2025
- Dividend Yield
- PGY N/A
- GYRE N/A
- EPS Growth
- PGY N/A
- GYRE N/A
- EPS
- PGY N/A
- GYRE N/A
- Revenue
- PGY $1,032,248,000.00
- GYRE $105,033,000.00
- Revenue This Year
- PGY $14.31
- GYRE $25.32
- Revenue Next Year
- PGY $17.20
- GYRE $12.95
- P/E Ratio
- PGY N/A
- GYRE N/A
- Revenue Growth
- PGY 27.12
- GYRE N/A
- 52 Week Low
- PGY $8.20
- GYRE $8.26
- 52 Week High
- PGY $20.00
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- PGY 61.45
- GYRE 47.99
- Support Level
- PGY $10.75
- GYRE $12.09
- Resistance Level
- PGY $19.20
- GYRE $12.80
- Average True Range (ATR)
- PGY 1.41
- GYRE 0.56
- MACD
- PGY 0.45
- GYRE -0.00
- Stochastic Oscillator
- PGY 55.06
- GYRE 16.39
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.